RT Journal Article SR Electronic T1 Is there a role for CA-125 in monitoring patients with early endometrial cancer? JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP 169 OP 172 DO 10.1046/j.1525-1438.1991.01040169.x VO 1 IS 4 A1 M. Prefontaine A1 G. J. O'Connell A1 E. Ryan A1 K. J. Murphy YR 1991 UL http://ijgc.bmj.com/content/1/4/169.abstract AB Elevated CA-125 levels have been reported in some women with endometrial carcinoma. Current follow-up policy for these patients does not involve the use of tumor markers. CA-125 measurements were performed in 28 patients with a diagnosis of endometrial cancer, 14 clinically free of disease and 14 with known disease. Based on the sensitivity (0.64) and specificity (0.93) observed we constructed a model to estimate the predictive value of the assay as a marker in the follow-up of patients who have completed treatment. This model would involve a CA-125 assay every six months for five years in 100 patients with stage I and II disease. Despite the high statistical correlation between the clinical status of the patient and the CA-125 value observed in our study, the positive predictive value would be approximately 24% in such a follow-up protocol where a low prevalence of recurrent malignancy is expected.